Abexinostat
Abexinostat is a pharmaceutical drug with 7 clinical trials. Currently 5 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
5
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
Clinical Trials (7)
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7